The role of targeting CDK4/6 in cancer immunotherapy

被引：0

作者：

Mengyu Sun ^{[1
]}

Lin Dong ^{[2
]}

Yu Wang ^{[3
]}

Chao Liu ^{[1
]}

Jiang Du ^{[2
]}

Bo Wang ^{[3
]}

Bofan Xing ^{[1
]}

Xiaofeng Yao ^{[2
]}

Yu Ren ^{[3
]}

Xuan Zhou ^{[1
]}

机构：

[1] Tianjin Medical University Cancer Institute and Hospital,Department of Maxillofacial and Otorhinolaryngological Oncology

[2] Key Laboratory of Cancer Prevention and Therapy,Department of Genetics, School of Basic Medical Sciences

[3] Tianjin Cancer Institute,undefined

[4] National Clinical Research Center of Cancer,undefined

[5] Key Laboratory of Basic and Translational Medicine On Head & Neck Cancer,undefined

[6] National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine,undefined

[7] Tianjin Medical University,undefined

来源：

Holistic Integrative Oncology | / 3卷 / 1期

关键词：

CDK4/6 inhibitor; Immunotherapy; Tumor immune microenvironment; Immune checkpoint blockade; Combination therapy;

D O I：

10.1007/s44178-024-00100-0

中图分类号：

学科分类号：

摘要：

Cyclin-dependent kinase 4/6 (CDK4/6) acts as a crucial point of regulation in the G1-to-S transition in the cell division cycle, its aberrant activation was found in various human cancers, leading to abnormal cell proliferation. Recent clinical trials have reported that combined with other small-molecule targeted therapies, CDK4/6 inhibitors increase overall survival and objective response rates in breast cancer (BC), non-small cell lung cancer (NSCLC), and head and neck squamous cell carcinoma (HNSCC). Notably, targeting CDK4/6 triggers an antitumor immune response, providing a potential combined application method for immunotherapy. In this review, we summarize underlying mechanism of targeting CDK4/6 in regulating antigen presentation, immune cell activation, and tumor immune microenvironment (TIME) remodeling and in producing synergistic effects with immune checkpoint blockade (ICB) in cancer clinical treatment.

引用

共 50 条

[1] Targeting CDK4 and CDK6 in cancer
Shom Goel
Johann S. Bergholz
Jean J. Zhao
Nature Reviews Cancer, 2022, 22 : 356 - 372
[2] Targeting CDK4 and CDK6 in cancer
Goel, Shom
Bergholz, Johann S.
Zhao, Jean J.
NATURE REVIEWS CANCER, 2022, 22 (06) : 356 - 372
[3] Targeting CDK4/6 in breast cancer
Shanabag, Anusha
Armand, Jessica
Son, Eugene
Yang, Hee Won
EXPERIMENTAL AND MOLECULAR MEDICINE, 2025, 57 (02): : 312 - 322
[4] Targeting CDK4/6 in patients with cancer
Hamilton, Erika
Infante, Jeffrey R.
CANCER TREATMENT REVIEWS, 2016, 45 : 129 - 138
[5] Targeting prostate cancer with the CDK4 and CDK6 inhibitor abemaciclib
Torres-Guzman, Raquel
Baquero, Carmen
Patricia Ganado, Maria
Marugan, Carlos
Bian, Huimin
Zeng, Yi
Rama, Ramon
Du, Jian
Jose Lallena, Maria
CANCER RESEARCH, 2020, 80 (16)
[6] Targeting CDK4/6 pathways and beyond in breast cancer
Ribnikar, Domen
Volovat, Simona Ruxandra
Cardoso, Fatima
BREAST, 2019, 43 : 8 - 17
[7] The Role of CDK4/6 Inhibitors in Breast Cancer
Murphy, Conleth G.
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (06)
[8] The Role of CDK4/6 Inhibition in Breast Cancer
Murphy, Conleth G.
Dickler, Maura N.
ONCOLOGIST, 2015, 20 (05): : 483 - U49
[9] The Role of CDK4/6 Inhibitors in Breast Cancer
Conleth G. Murphy
Current Treatment Options in Oncology, 2019, 20
[10] Mesoporous polydopamine Targeting CDK4/6 Inhibitor toward Brilliant Synergistic Immunotherapy of Breast Cancer
Zhou, Conglei
Zhao, Shuang
Zhang, Yongbo
Cheng, Jianjun
Shi, Jiahua
Du, Guanhua
SMALL, 2024, 20 (30)

← 1 2 3 4 5 →